Prior treatment with one platinum-based chemotherapy and an anti-PD-L1/PD-1 immunotherapy. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens
You may not be if
Prior treatment with an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting
